NIH-funded mouse study is the first to show that visual stimulation helps re-wire the visual system and partially restores sight.
A study in mice funded by the National Institutes of Health (NIH) shows for the first time that high-contrast visual stimulation can help damaged retinal neurons regrow optic nerve fibers, otherwise known as retinal ganglion cell axons. In combination with chemically induced neural stimulation, axons grew further than in strategies tried previously. Treated mice partially regained visual function. The study also demonstrates that adult regenerated central nervous system (CNS) axons are capable of navigating to correct targets in the brain. The research was funded through the National Eye Institute (NEI), a part of NIH. Read More.
A number of countries have ended some types of research with chimpanzees over the past decades. For example, the US National Institutes of Health announced in November 2015 that it would no longer support many types of chimpanzee research. In Europe, the fate of former research chimpanzees has depended upon a mix of private wildlife parks and zoos for the animals’ care and management. The outcomes in term of chimpanzee health and survival remain relatively unknown. Read More.
Amita Sehgal, a sleep researcher at the University of Pennsylvania, has discovered some of the key genes that control our 24-hour circadian cycle, making us fall asleep at night and rise again in the morning. Sehgal didn’t find these genes in people, however. She found them in flies. Read More.
University of Wisconsin–Madison researchers studying monkeys have shown that one infection with Zika virus protects against future infection, though pregnancy may drastically prolong the time the virus stays in the body.
The researchers, led by UW–Madison pathology Professor David O’Connor, published a study today (June 28, 2016) in the journal Nature Communications describing their work establishing rhesus macaque monkeys at the Wisconsin National Primate Research Center as a model for studying the way Zika virus infections may progress in people. Read More
Moving towards human clinical trials
Over the past 6 years, Drs. Peter Barry and Alice Tarantal, California National Primate Research Center (CNPRC) at UC Davis, have been collaborating with Dr. Louis Picker at Oregon Health Science University (OHSU)–Oregon NPRC to develop and test a vaccine and potential cure for HIV. OHSU is now recruiting volunteers to be part of the first human trials for this exciting new development in the prevention and treatment of HIV. Read More.
The media regularly report impressive medical advances. However, in most cases, there is a reluctance by scientists, the universities, or research institutions they work for, and the media to mention animals used in that research, let alone non-human primates. Such omission misleads the public and works against long-term sustainability of a very important means of advancing knowledge about health and disease.
Consider the recent report by Ali Rezai and colleagues, in the journal Nature, of a patient with quadriplegia who was able to use his hands by just thinking about the action. The signals in the brain recorded by implanted electrodes were analysed and fed into the muscles of the arm to activate the hand directly. Read More.
The vaccine, Gardasil, came onto market in June of 2006 and protects again four different HPV types: the two most prevalent high-risk viruses, HPV16 and HPV18, and the two most common causes of benign genital warts, HPV6 and HPV11. Protection against HPV16 and HPV18 is particularly important to human health given that these viruses are responsible for 70% of cervical cancers in women – a cancer which caused 270,000 deaths in 2012. The effectiveness of the HPV vaccine is excellent news in our quest to reduce the deadly toll of cervical cancer, and received widespread coverage in the mainstream media. Read More.
Type 1 diabetes is an autoimmune wikipediadisorder that shuts down the body’s production of insulin. This pill blocks the buildup of a specific acid in the pancreas, which then stops the disorder from taking hold, according to research published this week in the Journal of Clinical Investigation.
Type 1 diabetes is an autoimmune disorder that shuts down the body’s production of insulin. Normally, insulin is made by beta cells in the pancreas; it’s a hormone that’s important for converting the sugars we eat into energy. But for patients with type 1 diabetes, the body’s immune system destroys the pancreatic beta cells, effectively halting insulin production. The condition is different from type 2 diabetes, where the body doesn’t produce enough insulin or the insulin stops working properly. Type 1 diabetes, usually diagnosed during childhood or adolescence, affects more than 1.25 million Americans. Read More.
A highly unusual clinical trial in Guinea has shown for the first time that an Ebola vaccine protects people from the deadly virus. The study, published online today by The Lancet, shows that the injection offered contacts of Ebola cases 100% protection starting 10 days after they received a single shot of the vaccine, which is produced by Merck. Scientists say the vaccine could help to finally bring an end to the epidemic in West Africa, now more than 18 months old.
“This will go down in history as one of those hallmark public health efforts,” says Michael Osterholm, the director of the Center for Infectious Disease Research and Policy in Twin Cities, Minnesota, who wasn’t involved in the study. “We will teach about this in public health schools.”
“It’s a wonderful result and a fantastic illustration of how vaccines can be developed very quickly and can be used in an outbreak situation to control the disease,” says Adrian Hill, a vaccine researcher at the University of Oxford in the United Kingdom, also not involved in the work. Read More.
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. Vaccinated mice produced broadly neutralizing antibodies against multiple strains of the MERS coronavirus (MERS-CoV), while vaccinated macaques were protected from severe lung damage when later exposed to MERS-CoV. The findings suggest that the current approach, in which vaccine design is guided by an understanding of structure of viral components and their interactions with host cells, holds promise for developing a similar human MERS vaccine regimen. Read More.